UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 24, 2007

Access Pharmaceuticals, Inc.			
(Exact name of registrant as specified in its charter)			
Delaware			
	(Commission File Number) (I.R.S. Employe Identification No.)		
2600 Stemmons Free	• •		75207
(Address of principal executive offices) (Zip Code)			
Registrant's telephone	number, includ	ing area code: ((214) 905-5100
Item 1.01 Entry into a M	aterial Definiti	ve Agreement	

On April 24, 2007, Access Pharmaceuticals, Inc. ("Access") entered into an amendment to its 7.0% (Subject to Adjustment) Convertible Promissory Notes with Oracle Partners LP, Oracle Institutional Partners LP, SAM Oracle Investments Inc. and Oracle Offshore Ltd. agreeing to extend the maturity date of the notes to June 12, 2007 from April 28, 2007. The notes in aggregate total \$4,015,000.

On April 26, 2007, Access entered into an amendment to its 7.5% Convertible Notes with SCO Capital Partners LLC, Beach Capital LLC and Lake End Capital LLC agreeing to extend the maturity date of the notes to June 11, 2007 from April 27, 2007. The notes in aggregate total \$6,000,000.

All other terms of the notes remain the same.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: /s/ Stephen B. Thompson

Stephen B. Thompson Vice President and Chief Financial Officer

Dated April 26, 2007

3